Business Daily from THE HINDU group of publications
Monday, November 30, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
|
Business Daily from THE HINDU group of publications Monday, November 30, 2009 ePaper | Mobile/PDA Version | Audio | Blogs |
|
|
|
|
|
Update at 1540 hrs (IST)
Corporate Suven Life gets 3 European patents for new entities
MUMBAI: Suven Life Sciences on Monday said the European Patent Office (EPO) has issued three patents to its chemical entities which are used in treating nerve disorders. “The company gets three patents — EP1537113, EP1704154 and EP1856132 and the said are valid until 2023, and 2024, 2022, respectively,” Suven said in a filing to the Bombay Stock Exchange. The granted claims of the patents include therapeutic agents, useful in the treatment of neurodegenerative disorders like alzheimer’s, parkinson, and schizophrenia, the filing added. “We are very pleased by the grant of these patents to Suven by EPO for our pipeline of molecules in central nervous system arena that are being developed for cognitive disorders,” the company CEO, Mr Venkat Jasti, said. With these new patents, Suven has a total of seven granted EPO patents on new chemical entities. These patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts, it added. — PTI
Prev: Probe team questions Kaiga employees Business Line | NUS Index | |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line
|